Skip to main content

X4 Pharmaceuticals, Inc

XFOR
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001501697

In the last 90 days, X4 Pharmaceuticals, Inc insiders filed 0 open-market purchases and 2 sales; 89 institutions reported holding it in 13F filings for Q2 2026, worth $463.0M in total; no superinvestor holds it.

Q2 2022 vs. Q1 2022

How the institutions holding X4 Pharmaceuticals, Inc changed between Q1 2022 and Q2 2022.

All holders in Q2 2022All holders in Q1 2022

13F holders of XFOR: Q1 2022 compared with Q2 2022
MeasureQ1 2022Q2 2022Change
Holders5651−5
Shares16.3M16.1M−286.2K (−1.8%)
Value$28.6M$15.5M−$13.1M (−45.7%)

New holders (5)

Institutions that held X4 Pharmaceuticals, Inc at the end of Q2 2022 but not at the end of Q1 2022.

Institutions new to XFOR in Q2 2022
InstitutionSharesValue% of portfolio
Kestra Advisory Services, LLC33,000$32.0K0.00%
Ronald Blue Trust, Inc.8,520$15.0K0.00%
Private Advisor Group, LLC13,221$13.0K0.00%
Veritable, L.P.12,637$12.0K0.00%
Cutler Group LP1,019$00.00%

Sold out (10)

Institutions that held X4 Pharmaceuticals, Inc at the end of Q1 2022 and filed for Q2 2022 without it.

Institutions that sold out of XFOR in Q2 2022
InstitutionShares, Q1 2022Value, Q1 2022
Ensign Peak Advisors, Inc176,530$309.0K
Kennedy Capital Management, Inc.113,848$199.0K
Jane Street Group, LLC36,847$64.0K
Susquehanna International Group, LLP35,302$62.0K
Simplex Trading, LLC35,673$62.0K
Norges Bank27,700$48.5K
XTX Topco Ltd26,546$46.0K
Group One Trading, L.P.16,950$30.0K
Marshall Wace, LLP13,099$23.0K
Federated Hermes, Inc.152–